Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the International AIDS Society"
DOI: 10.1002/jia2.25862
Abstract: Efavirenz (EFV) is commonly used for first‐line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV… read more here.
Keywords: virologically suppressed; suppressed adolescents; switching efavirenz; week ... See more keywords
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix335
Abstract: Background We previously demonstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic control in children infected with human immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention… read more here.
Keywords: switching efavirenz; ritonavir boosted; remaining ritonavir; boosted lopinavir ... See more keywords
Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz276
Abstract: Abstract Background The NEVEREST-3 (South Africa) and MONOD-ANRS-12206 (Côte d’Ivoire, Burkina Faso) randomized trials found that switching to efavirenz (EFV) in human immunodeficiency virus–infected children >3 years old who were virologically suppressed by ritonavir-boosted lopinavir… read more here.
Keywords: switching efavirenz; human immunodeficiency; continued lpv; cost ... See more keywords